Summary
Global Markets Direct’s, ‘Hepatitis C - Pipeline Review, H1 2016’, provides an overview of the Hepatitis C pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Hepatitis C, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hepatitis C and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Hepatitis C
- The report reviews pipeline therapeutics for Hepatitis C by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Hepatitis C therapeutics and enlists all their major and minor projects
- The report assesses Hepatitis C therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Hepatitis C
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Hepatitis C
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hepatitis C pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
3-V Biosciences, Inc.
AbbVie Inc.
AiCuris GmbH & Co. KG
AIMM Therapeutics B.V.
Akshaya Bio Inc.
Altor BioScience Corporation
Amarillo Biosciences, Inc.
Amarna Therapeutics B.V.
ARA Healthcare Pvt. Ltd.
Arbutus Biopharma Corporation
Beijing Kawin Technology Share-Holding Co., Ltd.
Benitec Biopharma Limited
BIOCAD
Biogenomics Limited
BioLineRx, Ltd.
Bionor Pharma ASA
Biota Pharmaceuticals, Inc.
Biotest AG
Biotron Limited
Boehringer Ingelheim GmbH
Bolder Biotechnology, Inc.
Bristol-Myers Squibb Company
Celgene Corporation
Chugai Pharmaceutical Co., Ltd.
Cocrystal Pharma, Inc.
Conatus Pharmaceuticals Inc.
DEKK-TEC, Inc.
Delpor, Inc.
Digna Biotech, S.L.
DiscoveryBiomed, Inc.
Enanta Pharmaceuticals, Inc.
F. Hoffmann-La Roche Ltd.
Formune S.L.
Genecode AS
GeneCure LLC
Gilead Sciences, Inc.
GinkgoPharma Co. Ltd.
GlaxoSmithKline Plc
HanAll Biopharma Co., Ltd.
HEC Pharm Co., Ltd.
Hepacyl Therapeutics, SL
ImmunoBiology Limited
Immunocore Limited
Immunomedics, Inc.
Inovio Pharmaceuticals, Inc.
Integrated BioTherapeutics, Inc.
iTherX, Inc.
JN-International Medical Corporation
Johnson & Johnson
Karyopharm Therapeutics, Inc.
Kineta, Inc.
LG Life Science LTD.
Ligand Pharmaceuticals, Inc.
Medivir AB
Merck & Co., Inc.
Microbio Co., Ltd.
Microbiotix, Inc.
MultiCell Technologies, Inc.
Novartis AG
NovaTarg Therapeutics, Inc
Ono Pharmaceutical Co., Ltd.
Pfenex Inc.
Pfizer Inc.
PharmaEssentia Corporation
Polaris Pharmaceuticals, Inc.
Presidio Pharmaceuticals, Inc.
Profectus BioSciences, Inc.
Regulus Therapeutics Inc.
Rodos BioTarget GmbH
Savoy Pharmaceuticals, Inc.
SEEK Group
SomaGenics, Inc.
Sorrento Therapeutics, Inc.
Spring Bank Pharmaceuticals, Inc.
TaiGen Biotechnology Co., Ltd.
TaiwanJ Pharmaceuticals Co., Ltd.
TGV-Laboratories
Therapix Biosciences Ltd
Therapure Biopharma Inc.
Theravectys SA
Vakzine Projekt Management GmbH
VBI Vaccines Inc.
Vertex Pharmaceuticals Incorporated
WhanIn Pharmaceutical Co., Ltd.
'
Table of Contents
Table of Contents 2
Introduction 7
Hepatitis C Overview 8
Therapeutics Development 9
Hepatitis C – Therapeutics under Development by Companies 11
Hepatitis C – Therapeutics under Investigation by Universities/Institutes 19
Hepatitis C – Pipeline Products Glance 21
Hepatitis C – Products under Development by Companies 25
Hepatitis C – Products under Investigation by Universities/Institutes 38
Hepatitis C – Companies Involved in Therapeutics Development 40
Hepatitis C – Therapeutics Assessment 124
Drug Profiles 144
Hepatitis C – Recent Pipeline Updates 422
Hepatitis C - Dormant Projects 518
Hepatitis C – Discontinued Products 543
Hepatitis C – Product Development Milestones 551
Appendix 561
List of Tables
Number of Products under Development for Hepatitis C, H1 2016 32
Number of Products under Development for Hepatitis C – Comparative Analysis, H1 2016 33
Number of Products under Development by Companies, H1 2016 35
Number of Products under Development by Companies, H1 2016 (Contd..1) 36
Number of Products under Development by Companies, H1 2016 (Contd..2) 37
Number of Products under Development by Companies, H1 2016 (Contd..3) 38
Number of Products under Development by Companies, H1 2016 (Contd..4) 39
Number of Products under Development by Companies, H1 2016 (Contd..5) 40
Number of Products under Development by Companies, H1 2016 (Contd..6) 41
Number of Products under Investigation by Universities/Institutes, H1 2016 42
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 43
Comparative Analysis by Late Stage Development, H1 2016 44
Comparative Analysis by Clinical Stage Development, H1 2016 45
Comparative Analysis by Early Stage Development, H1 2016 46
Comparative Analysis by Unknown Stage Development, H1 2016 47
Products under Development by Companies, H1 2016 48
Products under Development by Companies, H1 2016 (Contd..1) 49
Products under Development by Companies, H1 2016 (Contd..2) 50
Products under Development by Companies, H1 2016 (Contd..3) 51
Products under Development by Companies, H1 2016 (Contd..4) 52
Products under Development by Companies, H1 2016 (Contd..5) 53
Products under Development by Companies, H1 2016 (Contd..6) 54
Products under Development by Companies, H1 2016 (Contd..7) 55
Products under Development by Companies, H1 2016 (Contd..8) 56
Products under Development by Companies, H1 2016 (Contd..9) 57
Products under Development by Companies, H1 2016 (Contd..10) 58
Products under Development by Companies, H1 2016 (Contd..11) 59
Products under Development by Companies, H1 2016 (Contd..12) 60
Products under Investigation by Universities/Institutes, H1 2016 61
Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 62
Hepatitis C – Pipeline by 3-V Biosciences, Inc., H1 2016 63
Hepatitis C – Pipeline by AbbVie Inc., H1 2016 64
Hepatitis C – Pipeline by AiCuris GmbH & Co. KG, H1 2016 65
Hepatitis C – Pipeline by AIMM Therapeutics B.V., H1 2016 66
Hepatitis C – Pipeline by Akshaya Bio Inc., H1 2016 67
Hepatitis C – Pipeline by Altor BioScience Corporation, H1 2016 68
Hepatitis C – Pipeline by Amarillo Biosciences, Inc., H1 2016 69
Hepatitis C – Pipeline by Amarna Therapeutics B.V., H1 2016 70
Hepatitis C – Pipeline by ARA Healthcare Pvt. Ltd., H1 2016 71
Hepatitis C – Pipeline by Arbutus Biopharma Corporation, H1 2016 72
Hepatitis C – Pipeline by Beijing Kawin Technology Share-Holding Co., Ltd., H1 2016 73
Hepatitis C – Pipeline by Benitec Biopharma Limited, H1 2016 74
Hepatitis C – Pipeline by BIOCAD, H1 2016 75
Hepatitis C – Pipeline by Biogenomics Limited, H1 2016 76
Hepatitis C – Pipeline by BioLineRx, Ltd., H1 2016 77
Hepatitis C – Pipeline by Bionor Pharma ASA, H1 2016 78
Hepatitis C – Pipeline by Biota Pharmaceuticals, Inc., H1 2016 79
Hepatitis C – Pipeline by Biotest AG, H1 2016 80
Hepatitis C – Pipeline by Biotron Limited, H1 2016 81
Hepatitis C – Pipeline by Boehringer Ingelheim GmbH, H1 2016 82
Hepatitis C – Pipeline by Bolder Biotechnology, Inc., H1 2016 83
Hepatitis C – Pipeline by Bristol-Myers Squibb Company, H1 2016 84
Hepatitis C – Pipeline by Celgene Corporation, H1 2016 85
Hepatitis C – Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2016 86
Hepatitis C – Pipeline by Cocrystal Pharma, Inc., H1 2016 87
Hepatitis C – Pipeline by Conatus Pharmaceuticals Inc., H1 2016 88
Hepatitis C – Pipeline by DEKK-TEC, Inc., H1 2016 89
Hepatitis C – Pipeline by Delpor, Inc., H1 2016 90
Hepatitis C – Pipeline by Digna Biotech, S.L., H1 2016 91
Hepatitis C – Pipeline by DiscoveryBiomed, Inc., H1 2016 92
Hepatitis C – Pipeline by Enanta Pharmaceuticals, Inc., H1 2016 93
Hepatitis C – Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 94
Hepatitis C – Pipeline by Formune S.L., H1 2016 95
Hepatitis C – Pipeline by Genecode AS, H1 2016 96
Hepatitis C – Pipeline by GeneCure LLC, H1 2016 97
Hepatitis C – Pipeline by Gilead Sciences, Inc., H1 2016 98
Hepatitis C – Pipeline by GinkgoPharma Co. Ltd., H1 2016 99
Hepatitis C – Pipeline by GlaxoSmithKline Plc, H1 2016 100
Hepatitis C – Pipeline by HanAll Biopharma Co., Ltd., H1 2016 101
Hepatitis C – Pipeline by HEC Pharm Co., Ltd., H1 2016 102
Hepatitis C – Pipeline by Hepacyl Therapeutics, SL, H1 2016 103
Hepatitis C – Pipeline by ImmunoBiology Limited, H1 2016 104
Hepatitis C – Pipeline by Immunocore Limited, H1 2016 105
Hepatitis C – Pipeline by Immunomedics, Inc., H1 2016 106
Hepatitis C – Pipeline by Inovio Pharmaceuticals, Inc., H1 2016 107
Hepatitis C – Pipeline by Integrated BioTherapeutics, Inc., H1 2016 108
Hepatitis C – Pipeline by iTherX, Inc., H1 2016 109
Hepatitis C – Pipeline by JN-International Medical Corporation, H1 2016 110
Hepatitis C – Pipeline by Johnson & Johnson, H1 2016 111
Hepatitis C – Pipeline by Karyopharm Therapeutics, Inc., H1 2016 112
Hepatitis C – Pipeline by Kineta, Inc., H1 2016 113
Hepatitis C – Pipeline by LG Life Science LTD., H1 2016 114
Hepatitis C – Pipeline by Ligand Pharmaceuticals, Inc., H1 2016 115
Hepatitis C – Pipeline by Medivir AB, H1 2016 116
Hepatitis C – Pipeline by Merck & Co., Inc., H1 2016 117
Hepatitis C – Pipeline by Microbio Co., Ltd., H1 2016 118
Hepatitis C – Pipeline by Microbiotix, Inc., H1 2016 119
Hepatitis C – Pipeline by MultiCell Technologies, Inc., H1 2016 120
Hepatitis C – Pipeline by Novartis AG, H1 2016 121
Hepatitis C – Pipeline by NovaTarg Therapeutics, Inc, H1 2016 122
Hepatitis C – Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 123
Hepatitis C – Pipeline by Pfenex Inc., H1 2016 124
Hepatitis C – Pipeline by Pfizer Inc., H1 2016 125
Hepatitis C – Pipeline by PharmaEssentia Corporation, H1 2016 126
Hepatitis C – Pipeline by Polaris Pharmaceuticals, Inc., H1 2016 127
Hepatitis C – Pipeline by Presidio Pharmaceuticals, Inc., H1 2016 128
Hepatitis C – Pipeline by Profectus BioSciences, Inc., H1 2016 129
Hepatitis C – Pipeline by Regulus Therapeutics Inc., H1 2016 130
Hepatitis C – Pipeline by Rodos BioTarget GmbH, H1 2016 131
Hepatitis C – Pipeline by Savoy Pharmaceuticals, Inc., H1 2016 132
Hepatitis C – Pipeline by SEEK Group, H1 2016 133
Hepatitis C – Pipeline by SomaGenics, Inc., H1 2016 134
Hepatitis C – Pipeline by Sorrento Therapeutics, Inc., H1 2016 135
Hepatitis C – Pipeline by Spring Bank Pharmaceuticals, Inc., H1 2016 136
Hepatitis C – Pipeline by TaiGen Biotechnology Co., Ltd., H1 2016 137
Hepatitis C – Pipeline by TaiwanJ Pharmaceuticals Co., Ltd., H1 2016 138
Hepatitis C – Pipeline by TGV-Laboratories, H1 2016 139
Hepatitis C – Pipeline by Therapix Biosciences Ltd, H1 2016 140
Hepatitis C – Pipeline by Therapure Biopharma Inc., H1 2016 141
Hepatitis C – Pipeline by Theravectys SA, H1 2016 142
Hepatitis C – Pipeline by Vakzine Projekt Management GmbH, H1 2016 143
Hepatitis C – Pipeline by VBI Vaccines Inc., H1 2016 144
Hepatitis C – Pipeline by Vertex Pharmaceuticals Incorporated, H1 2016 145
Hepatitis C – Pipeline by WhanIn Pharmaceutical Co., Ltd., H1 2016 146
Assessment by Monotherapy Products, H1 2016 147
Assessment by Combination Products, H1 2016 148
Number of Products by Stage and Target, H1 2016 150
Number of Products by Stage and Mechanism of Action, H1 2016 157
Number of Products by Stage and Route of Administration, H1 2016 164
Number of Products by Stage and Molecule Type, H1 2016 166
Hepatitis C Therapeutics – Recent Pipeline Updates, H1 2016 445
Hepatitis C – Dormant Projects, H1 2016 541
Hepatitis C – Dormant Projects (Contd..1), H1 2016 542
Hepatitis C – Dormant Projects (Contd..2), H1 2016 543
Hepatitis C – Dormant Projects (Contd..3), H1 2016 544
Hepatitis C – Dormant Projects (Contd..4), H1 2016 545
Hepatitis C – Dormant Projects (Contd..5), H1 2016 546
Hepatitis C – Dormant Projects (Contd..6), H1 2016 547
Hepatitis C – Dormant Projects (Contd..7), H1 2016 548
Hepatitis C – Dormant Projects (Contd..8), H1 2016 549
Hepatitis C – Dormant Projects (Contd..9), H1 2016 550
Hepatitis C – Dormant Projects (Contd..10), H1 2016 551
Hepatitis C – Dormant Projects (Contd..11), H1 2016 552
Hepatitis C – Dormant Projects (Contd..12), H1 2016 553
Hepatitis C – Dormant Projects (Contd..13), H1 2016 554
Hepatitis C – Dormant Projects (Contd..14), H1 2016 555
Hepatitis C – Dormant Projects (Contd..15), H1 2016 556
Hepatitis C – Dormant Projects (Contd..16), H1 2016 557
Hepatitis C – Dormant Projects (Contd..17), H1 2016 558
Hepatitis C – Dormant Projects (Contd..18), H1 2016 559
Hepatitis C – Dormant Projects (Contd..19), H1 2016 560
Hepatitis C – Dormant Projects (Contd..20), H1 2016 561
Hepatitis C – Dormant Projects (Contd..21), H1 2016 562
Hepatitis C – Dormant Projects (Contd..22), H1 2016 563
Hepatitis C – Dormant Projects (Contd..23), H1 2016 564
Hepatitis C – Dormant Projects (Contd..24), H1 2016 565
Hepatitis C – Discontinued Products, H1 2016 566
Hepatitis C – Discontinued Products (Contd..1), H1 2016 567
Hepatitis C – Discontinued Products (Contd..2), H1 2016 568
Hepatitis C – Discontinued Products (Contd..3), H1 2016 569
Hepatitis C – Discontinued Products (Contd..4), H1 2016 570
Hepatitis C – Discontinued Products (Contd..5), H1 2016 571
Hepatitis C – Discontinued Products (Contd..6), H1 2016 572
Hepatitis C – Discontinued Products (Contd..7), H1 2016 573
List of Figures
Number of Products under Development for Hepatitis C, H1 2016 32
Number of Products under Development for Hepatitis C – Comparative Analysis, H1 2016 33
Number of Products under Development by Companies, H1 2016 34
Number of Products under Investigation by Universities/Institutes, H1 2016 42
Comparative Analysis by Late Stage Development, H1 2016 44
Comparative Analysis by Clinical Stage Development, H1 2016 45
Comparative Analysis by Early Stage Products, H1 2016 46
Assessment by Monotherapy Products, H1 2016 147
Assessment by Combination Products, H1 2016 148
Number of Products by Top 10 Targets, H1 2016 149
Number of Products by Stage and Top 10 Targets, H1 2016 149
Number of Products by Top 10 Mechanism of Actions, H1 2016 156
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 156
Number of Products by Routes of Administration, H1 2016 163
Number of Products by Stage and Routes of Administration, H1 2016 163
Number of Products by Top 10 Molecule Types, H1 2016 165
Number of Products by Stage and Top 10 Molecule Types, H1 2016 165
